Did you mean excedrin ester strength?
Displaying drugs 101 - 125 of 894 in total
Viloxazine
Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) …
Fluticasone
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) …
Cobimetinib
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Pitolisant
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Niacin
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Approved
Investigational
Nutraceutical
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Meprednisone
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Secnidazole
Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Cortisone acetate
Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203]
Cortisone acetate...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Meperidine
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Crizotinib
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) …
Oxetacaine
Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH levels. Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. Oxetacaine is approved by Health Canada since 1995 for...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Methadone
Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a...
Approved
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Dextropropoxyphene
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe...
Approved
Illicit
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Pretomanid
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Azithromycin
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Topiramate
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) …
Oxybutynin
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999]
Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Gamolenic acid
Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds that is most commonly found in human milk and other botanical sources . It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6;...
Approved
Investigational
Interferon alfa-n3
Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Insulin beef
Insulin beef has been discontinued in the US and Canada since 2017.
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Displaying drugs 101 - 125 of 894 in total